Biotechnology
Commented by Carsten Mainitz on April 13th, 2021 | 09:06 CEST
InnoCan Pharma, Cardiol Therapeutics, BevCanna - Watch out: undiscovered cannabis price rockets!
Whether French explorer Jacques Cartier, who first named the region around present-day Quebec "Canada" in 1535, was acting on a hunch, or simply "Frenching" the word "Kanata" from the language of the Saint Lawrence Iroquois, can unfortunately no longer be determined with certainty today. However, what is certain is that today's "Canada" is the current stronghold of medical "cannabis." Thanks to liberal laws, hemp startups are sprouting up worldwide, and even established companies want a piece of the pie. Here are three interesting candidates for the portfolio, with current news and powerful price potential!
Read
Commented by André Will-Laudien on April 12th, 2021 | 08:30 CEST
BioNTech, Formycon, Psybio Therapeutics: A chance for normality?
It is a matter of course: The desire for normality! Things have not been normal over the last 12 months, which everyone is now feeling. Our society has had a lot to shoulder since the turn of the millennium. The extreme increase in radicalism, the emergence of dangerous dictators and incompetent politicians, the polarization of beliefs, the explosive development of wealth in shares and real estate owners with simultaneous global impoverishment, the excessive indebtedness of the states, and now, a worldwide pandemic of unimagined proportions. It takes a good deal of imagination to believe in a "normalization" and then a more philosophical question quickly arises: What does an economic reality with and after the pandemic look like?
Read
Commented by Carsten Mainitz on March 30th, 2021 | 11:23 CEST
Paion, PsyBio Therapeutics, NanoRepro - New dimensions
When companies enter previously uncharted territory with new solutions or innovations, it can lead to a profound revaluation of the share. The potential associated with the new activities is usually priced in over a more extended period, sometimes with high fluctuations. We present three companies that are currently going through the exciting phase of a revaluation.
Read
Commented by André Will-Laudien on March 29th, 2021 | 08:15 CEST
Cardiol Therapeutics, Bayer, Formycon: These pharma stocks could explode!
According to official statistics, diseases of the cardiovascular system, such as heart failure, coronary heart disease or myocardial infarction, are the No.1 cause of death in Germany. With 18.2 million deaths, they represented the most common cause of death worldwide in 2019. Thus, on a global average, a good 30% of all deaths are attributable to cardiovascular disease. In Europe, more than 4 million people die each year due to such a disease, 1.4 million of whom are younger than 75. But there are many other dangers to our health. Reason enough to take a closer look.
Read
Commented by Stefan Feulner on March 25th, 2021 | 08:19 CET
Evotec, PsyBio Therapeutics, MorphoSys - Milestone in Development!
About 350 million people worldwide live with depression. According to estimates by the World Health Organization (WHO), only one in four sufferers receives adequate treatment. With all its limitations, the Corona Crisis has caused the number of unreported cases to skyrocket exorbitantly, making depression the most significant cause of illness above all. Apart from the prescription of antidepressants, which usually have strong side effects, there are few alternative treatment methods. But now, young biotech companies are stepping up to revolutionize the field of "mental health."
Read
Commented by Stefan Feulner on March 16th, 2021 | 07:16 CET
Bayer, Cardiol Therapeutics, Xiaomi - Biotech: Blockbuster potential here!
Germany is leading the race for a vaccine against the coronavirus With two companies - BioNTech and CureVac. The biotech industry is currently experiencing a growth spurt that will continue over the next few years, if not decades. In Germany alone, EUR 7 billion is invested annually in research and development. The goal is to develop new therapies to prevent, alleviate and cure diseases. The opportunity for disproportionate share price gains by investing in a company at an early stage of research is gigantic.
Read
Commented by André Will-Laudien on March 11th, 2021 | 07:30 CET
Compass Pathways, Canopy Growth, PsyBio Therapeutics - Cannabis or psilocybin?
Cannabis stocks have been a bit forgotten after an early-year rally caused a 500% increase in some cases. Most stocks have already corrected back up 50% from the top and have been running more sideways recently. Speculation in psychoactive substances has recently shifted to a new industry, the mushroom applications around psilocybin. These substances are said to treat particular forms of depression, a fact that is becoming more explosive against the backdrop of increasing loneliness due to Covid lockdowns. Let's take a look at some prominent representatives.
Read
Commented by Nico Popp on March 10th, 2021 | 09:27 CET
BioNTech, CureVac, Cardiol Therapeutics: Biotech rockets off the launchpad
We all know that health is the greatest good. But it is only the last year or so that we've become fully aware of the fact that everything changes during a pandemic. Work, family, leisure time - no area of life is not currently under the influence of Covid-19. But even if lockdown fatigue is slowly but surely setting in, investors should remain wide awake. In many sectors, the course is currently being set for the future - especially in the pharmaceutical and biotech industries. Reason enough to take a closer look at these three stocks.
Read
Commented by Carsten Mainitz on March 3rd, 2021 | 07:34 CET
Evotec, Cardiol Therapeutics, MorphoSys - Watch out: Great upside potential here in the short term
In the pandemic, investors have learned that small biotech companies, some still with a start-up character, can be worth billions overnight. BioNTech and CureVac are familiar names from the press. Both are linked by the Corona drug and the fact that they are headquartered in Germany. Two other German companies, Evotec and MorphoSys, have written a good growth story on the stock exchange in recent years: small becomes big! Small is also still the Canadian Cardiol Therapeutics. With the announced dual listing on the US technology exchange Nasdaq, a valuation boost could be imminent.
Read
Commented by André Will-Laudien on February 17th, 2021 | 10:39 CET
Cardiol Therapeutics, Formycon, Teva Pharmaceuticals: COVID in focus!
According to recent statistics from the WHO, nowhere is research currently more intense than in the area of viral diseases. At least 248 vaccine projects have been initiated against COVID-19 since January 2020, but only the research projects have already been reported. But of course, we humans do not only fall ill from flu viruses and their dangerous mutants, but the permanent change in our lives alone intensifies diseases that arise from lack of exercise and contact and sometimes cause worse consequences than a flu-like effect. Everyone is currently looking to hopeful vaccine solutions, but several biotech and pharmaceutical companies can still make us healthier with new developments.
Read